Prostate Cancer Questions & Answers

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov. 68 (6):394-424. [Medline].

2. American Cancer Society. Cancer Facts & Figures 2021. Available at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Accessed: February 2, 2021.

3. Shah, Rajal B., and Ming Zhou. istologic Variants of Acinar Adenocarcinoma, Ductal Adenocarcinoma, Neuroendocrine Tumors, and Other Carcinomas. Prostate Biopsy Interpretation. 2019. 69-95.

4. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul. 70 (1):106-119. [Medline].

5. Merriel SWD, Funston G, Hamilton W. Prostate Cancer in Primary Care. Adv Ther. 2018 Sep. 35 (9):1285-1294. [Medline].

6. Thompson IM Jr, Leach RJ, Ankerst DP. Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences Into Decision Making. JAMA. 2014 Aug 4. [Medline].

7. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016 Mar. 69 (3):428-35. [Medline].

8. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008 Feb. 15 (1):3866-71. [Medline].

9. Sánchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003 Feb 15. 54 (3):238-47. [Medline].

10. Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 2009 May. 73 (5 Suppl):S4-10. [Medline].

11. Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008 Mar. 19 (2):175-81. [Medline].

12. Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci. 2013 Jan. 68 (1):56-61. [Medline].

13. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer. 2010 Jan. 46 (2):377-83. [Medline].

14. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr. 10 (2):63-89. [Medline].

15. Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Available at https://seer.cancer.gov/statfacts/html/prost.html. Accessed: February 2, 2021.

16. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 Jul 19. [Medline]. [Full Text].

17. Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer. 2019 Sep 25. [Medline].

18. O'Keefe EB, Meltzer JP, Bethea TN. Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010. Front Public Health. 2015. 3:51. [Medline].

19. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018 Dec 3. 8 (12):[Medline].

20. Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res. 2018 Dec 1. 24 (23):5910-5917. [Medline].

21. Giri VN, Knudsen... Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 1. 36 (4):414-424. [Medline].

22. Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, et al. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate. 2019 Mar. 79 (4):333-339. [Medline].

23. Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019 Apr 1. 5 (4):523-528. [Medline].

24. Na R, Zheng SL, ... Xu J, Isaacs WB. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 May. 71 (5):740-747. [Medline].

25. Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. 2019 Oct. 76 (4):452-458. [Medline].

26. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. J Clin Oncol. 2013 Mar 25. [Medline].

27. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011 Apr. 4 (4):486-501. [Medline].

28. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008 Nov. 9 (11):1039-47. [Medline].

29. Stevens VL, Jacobs EJ, Sun J, Gapstur SM. No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2014 May. 23 (5):890-2. [Medline].

30. Pischon T, Boeing H, Weikert S, Allen N, Key T, ...Slimani N, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008 Nov. 17 (11):3252-61. [Medline].

31. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997 Aug. 6 (8):557-63. [Medline].

32. Mucci LA, Wilson KM, Giovannucci EL. Epidemiology of Prostate Cancer. Loda M, Mucci LA, Mittelstadt ML, Van Hemelrijck M, Cotter MB. Pathology and Epidemiology of Cancer. Springer International Publishing; 2017. 107-125.

33. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12. 306 (14):1549-56. [Medline].

34. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009 Jan 7. 301 (1):52-62. [Medline].

35. Eggener SE, Scardino PT, Walsh PC, Han M, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar. 185(3):869-75. [Medline].

36. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16. 101(12):878-87. [Medline]. [Full Text].

37. Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011 Jun 22. 305(24):2548-55. [Medline]. [Full Text].

38. Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011 May 18. 103(10):835-8. [Medline]. [Full Text].

39. Li WQ, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, et al. Personal History of Prostate Cancer and Increased Risk of Incident Melanoma in the United States. J Clin Oncol. 2013 Nov 4. [Medline].

40. Esrig D, Freeman JA, Elmajian DA, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol. 1996 Sep. 156 (3):1071-6. [Medline].

41. Reese JH, Freiha FS, Gelb AB, Lum BL, Torti FM. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol. 1992 Jan. 147 (1):92-5. [Medline].

42. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004 Feb. 171 (2 Pt 1):646-51. [Medline].

43. Njinou Ngninkeu B, Lorge F, Moulin P, Jamart J, Van Cangh PJ. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol. 2003 Jan. 169 (1):149-52. [Medline].

44. Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun. 37 (6):726-34. [Medline].

45. Cheville JC, Dundore PA, Bostwick DG, et al. Transitional cell carcinoma of the prostate: clinicopathologic study of 50 cases. Cancer. 1998 Feb 15. 82 (4):703-7. [Medline].

46. Pettus JA, Al-Ahmadie H, Barocas DA, et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol. 2008 Feb. 53 (2):370-5. [Medline].

47. Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, et al. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. Eur Urol Focus. 2018 Dec. 4 (6):790-803. [Medline].

48. Lerner SP, Shen S. Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol. 2008 Sep-Oct. 26 (5):481-5. [Medline].

49. Wood DP Jr, Montie JE, Pontes JE, VanderBrug Medendorp S, Levin HS. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol. 1989 Feb. 141 (2):346-9. [Medline].

50. Komyakov BK, Sergeev AV, Fadeev VA, et al. [Concomitant oncopathological changes in the prostate of urinary bladder cancer patients undergoing radical cystoprostateectomy] [Russian]. Urologiia. 2017 Sep. 42-5. [Medline].

51. [Guideline] Prostate Cancer. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Version 2.2021 — February 17, 2021; Accessed: March 10, 2021.

52. Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al. Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. Ann Fam Med. 2018 Mar. 16 (2):149-154. [Medline]. [Full Text].

53. Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, et al. Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. JAMA Oncol. 2017 May 1. 3 (5):705-707. [Medline].

54. Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15. 123 (4):592-599. [Medline].

55. Schröder FH, Hugosson J, Roobol MJ, ....Auvinen A, ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Dec 6. 384 (9959):2027-35. [Medline].

56. Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015 Sep. 68 (3):354-60. [Medline].

57. Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, ...Hugosson J, Auvinen A. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009 Oct. 56 (4):584-91. [Medline].

58. Tabár L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011 Sep. 260 (3):658-63. [Medline].

59. Siu AL, U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Feb 16. 164 (4):279-96. [Medline].

60. Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol. 2012 Jul 20. 30 (21):2581-4. [Medline].

61. Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 Feb 15. 126 (4):717-724. [Medline].

62. Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. 2020 Jun. 77 (6):713-724. [Medline].

63. US Preventive Services Task Force., Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 8. 319 (18):1901-1913. [Medline].

64. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019 May. 69 (3):184-210. [Medline].

65. Mottet N, Bellmunt J, ...Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr. 71 (4):618-629. [Medline].

66. Carroll PR, Parsons JK, Andriole G, ...Shead DA, Ho M, National comprehensive cancer network. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Sep. 12 (9):1211-9; quiz 1219. [Medline].

67. Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013 May 21. 158 (10):709-17. [Medline].

68. American Cancer Society Recommendations for Prostate Cancer Early Detection. American Cancer Society. Available at http://www.cancer.org/Cancer/ProstateCancer/MoreInformation/ProstateCancerEarlyDetection/prostate-cancer-early-detection-acs-recommendations. August 1, 2019; Accessed: May 22, 2020.

69. Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol. 2011 Apr. 59(4):498-505. [Medline].

70. Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol. 2011 Apr. 59(4):498-505. [Medline].

71. Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med. 2010 Jul 26. 170(14):1256-61. [Medline].

72. Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, et al. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol. 2016 Jun 13. [Medline].

73. [Guideline] National Comprehensive Cancer Network. Prostate Cancer Early Detection. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Version 2.2019 — May 31, 2019; Accessed: May 22, 2020.

74. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011 Mar 16. 103(6):462-9. [Medline]. [Full Text].

75. Mohammed W, Davis NF, Elamin S, Ahern P, Brady CM, Sweeney P. Six-core versus twelve-core prostate biopsy: a retrospective study comparing accuracy, oncological outcomes and safety. Ir J Med Sci. 2016 Feb. 185 (1):219-23. [Medline].

76. Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun. 189 (6):2039-46. [Medline].

77. Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol. 2017 Mar. 71 (3):353-365. [Medline].

78. Stefanova V, Buckley R, Flax S, Spevack L, Hajek D, Tunis A, et al. Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability. J Urol. 2019 Jun. 201 (6):1121-1126. [Medline].

79. Pepe P, Aragona F. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology. 2013 Jun. 81 (6):1142-6. [Medline].

80. Xue J, Qin Z, Cai H, Zhang C, Li X, Xu W, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget. 2017 Apr 4. 8 (14):23322-23336. [Medline].

81. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016 Jan. 69 (1):16-40. [Medline].

82. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 Dec. 196 (6):1613-1618. [Medline].

83. van der Leest M, Cornel E, Israël B,...Hulsbergen-van de Kaa C, Barentsz JO. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2019 Apr. 75 (4):570-578. [Medline].

84. Kasivisvanathan V, Rannikko AS, .... Moore CM, PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10. 378 (19):1767-1777. [Medline].

85. Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, et al. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. Eur Urol Focus. 2019 May. 5 (3):407-415. [Medline].

86. Tran GN, Leapman MS, Nguyen HG, Cowan JE, Shinohara K, Westphalen AC, et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017 Aug. 72 (2):275-281. [Medline].

87. Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, et al. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. J Urol. 2017 Mar. 197 (3 Pt 1):632-639. [Medline].

88. Aharony S, Baniel J, Yossepowitch O. Clinically unconfirmed positive urinary cytology: diagnostic implications and oncological outcomes. BJU Int. 2011 Oct. 108 (8 pt 2):E179-83. [Medline].

89. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016 Mar. 69 (3):428-35. [Medline].

90. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb. 40 (2):244-52. [Medline].

91. Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 May 6. 67 (3):245-253. [Medline]. [Full Text].

92. Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int. 2016 Mar. 117 (3):401-8. [Medline].

93. Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis. 2016 Sep. 19 (3):223-30. [Medline].

94. Mulcahy N. Tool Updated for Predicting Prostate Cancer Severity. Available at http://www.medscape.com/viewarticle/777352. Accessed: January 15, 2013.

95. Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013 Jan. 111(1):22-9. [Medline].

96. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16. 101(12):878-87. [Medline]. [Full Text].

97. Lowry F. Revamped prostate cancer risk calculator now online. Medscape Medical News. August 8, 2014. [Full Text].

98. Crawford ED, Blumenstein BA. Proposed substages for metastatic prostate cancer. Urology. 1997 Dec. 50(6):1027-8. [Medline].

99. Olsen JR, Azeem W, Hellem MR, et al. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 2016 Jul 4. 16:377. [Medline]. [Full Text].

100. Varinot J, Cussenot O, Roupret M, et al. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch. 2013 Dec. 463 (6):803-9. [Medline].

101. Kim HJ, Yoo JH. Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study. Cytojournal. 2017. 14:27. [Medline]. [Full Text].

102. [Guideline] Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 2018 Apr. 199 (4):990-997. [Medline]. [Full Text].

103. PDQ Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®). National Cancer Institute. Available at http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional/page4. July 22, 2020; Accessed: September 14, 2020.

104. EAU Virtual: EUPROMS Study Investigates Effect of Prostate Cancer Treatment on Quality of Life. ASCO Post. Available at https://www.ascopost.com/news/july-2020/euproms-study-investigates-effect-of-prostate-cancer-treatment-on-quality-of-life. July 20, 2020; Accessed: July 23, 2020.

105. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, et al. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 Jul 13. 377 (2):132-142. [Medline].

106. Froehner M, Koch R, Hübler M, Renner T, Borkowetz A, Zastrow S, et al. Only <10% of Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol Focus. 2019 May. 5 (3):361-364. [Medline].

107. Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995. 172:65-72. [Medline].

108. Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018 Dec 13. 379 (24):2319-2329. [Medline].

109. Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016 Mar. 13 (3):151-67. [Medline].

110. Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017 Jun 27. 317 (24):2532-2542. [Medline].

111. Hamdy FC, Donovan JL, Lane JA, Mason M, ...Neal DE, ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Oct 13. 375 (15):1415-1424. [Medline].

112. Chen RC. Radiation therapy for prostate cancer: An evolving treatment modality. Urol Oncol. 2019 Sep. 37 (9):579-581. [Medline].

113. Brooks NA, Boland RS, Strigenz ME, Mott SL, Brown JA. Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years. Urol Oncol. 2018 Nov. 36 (11):501.e9-501.e13. [Medline].

114. Spector BL, Brooks NA, Strigenz ME, Brown JA. Bladder Neck Contracture Following Radical Retropubic versus Robotic-Assisted Laparoscopic Prostatectomy. Curr Urol. 2017 Aug. 10 (3):145-149. [Medline].

115. Menon M, Dalela D, Jamil M, Diaz M, Tallman C, Abdollah F, et al. Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy: An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches. J Urol. 2018 May. 199 (5):1210-1217. [Medline].

116. Geinitz H, Thamm R, Keller M, Astner ST, Heinrich C, et al. Longitudinal study of intestinal symptoms and fecal continence in patients with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 1. 79(5):1373-80. [Medline].

117. Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg. 2011 Dec. 254(6):947-50. [Medline].

118. Nihei K, Ogino T, Onozawa M, Murayama S, Fuji H, Murakami M, et al. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys. 2011 Oct 1. 81(2):390-6. [Medline].

119. Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016 Mar 2. 352:i851. [Medline]. [Full Text].

120. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol. 1998 Dec. 160 (6 Pt 2):2418-24. [Medline].

121. Sriprasad S, Feneley MR, Thompson PM. History of prostate cancer treatment. Surg Oncol. 2009 Sep. 18 (3):185-91. [Medline].

122. van Poppel H, Everaerts W, Tosco L, Joniau S. Open and robotic radical prostatectomy. Asian J Urol. 2019 Apr. 6 (2):125-128. [Medline].

123. Lowrance WT, Eastham JA, Savage C, Maschino AC, Laudone VP, Dechet CB, et al. Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol. 2012 Jun. 187 (6):2087-92. [Medline].

124. Oberlin DT, Flum AS, Lai JD, Meeks JJ. The effect of minimally invasive prostatectomy on practice patterns of American urologists. Urol Oncol. 2016 Jun. 34 (6):255.e1-5. [Medline].

125. McAlpine K, Forster AJ, Breau RH, McIsaac D, Tufts J, Mallick R, et al. Robotic surgery improves transfusion rate and perioperative outcomes using a broad implementation process and multiple surgeon learning curves. Can Urol Assoc J. 2019 Jun. 13 (6):184-189. [Medline].

126. Preisser F, Busto Martin L, Pompe RS, Heinze A, Haese A, Graefen M, et al. Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence. Urol Oncol. 2020 Jan. 38 (1):1.e11-1.e16. [Medline].

127. Sooriakumaran P, Pini G, Nyberg T, Derogar M, Carlsson S, Stranne J, et al. Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial. Eur Urol. 2018 Apr. 73 (4):618-627. [Medline].

128. Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP, Shemshaki H. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner?. World J Urol. 2018 Apr. 36 (4):609-621. [Medline].

129. [Guideline] Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Feb 1. 79(2):335-41. [Medline].

130. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23. 299(3):289-95. [Medline].

131. Jones CU, Hunt D, McGowan DG, Amin MB et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14. 365(2):107-18. [Medline].

132. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 1. 33 (4):332-9. [Medline]. [Full Text].

133. Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review. AHRQ. Available at https://effectivehealthcare.ahrq.gov/topics/prostate-cancer-therapies-update/research. December 16, 2014; Accessed: September 14, 2020.

134. Bolla M, et al; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet,. 2012 Dec 8. 380 (9858):2018-27. [Medline].

135. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15. 296 (19):2329-35. [Medline].

136. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014 Aug. 66 (2):243-50. [Medline].

137. Hackman G, Taari K, Tammela TL, ...Hemminki A, FinnProstate Group. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. Eur Urol. 2019 Nov. 76 (5):586-595. [Medline].

138. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug. 190 (2):441-9. [Medline].

139. Shah TT, Peters M, Arya M, Ahmed HU. Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105. Eur Urol. 2019 Sep. 76 (3):e63-e64. [Medline].

140. Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, et al. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). Eur Urol Focus. 2019 Nov. 5 (6):1022-1028. [Medline].

141. Wang L, Yang H, Li B. Photodynamic therapy for prostate cancer: a systematic review and meta-analysis. Prostate Int. 2019 Sep. 7 (3):83-90. [Medline].

142. Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010 Jan. 105 (2):191-201. [Medline].

143. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul. 62(1):55-63. [Medline].

144. [Guideline] Lowrance W, Breau R, Chou R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline. American Urological Association. Available at https://www.auanet.org/guidelines/advanced-prostate-cancer. June 25, 2020; Accessed: July 22, 2020.

145. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20. 34 (12):1402-18. [Medline].

146. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27. 294(4):433-9. [Medline].

147. Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, et al. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 Jun. 197 (6):1448-1454. [Medline].

148. Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May. 51 (7):817-24. [Medline].

149. Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012 Sep 6. 367(10):895-903. [Medline]. [Full Text].

150. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000 Apr 29. 355(9214):1491-8. [Medline].

151. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.

152. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988. 165-70. [Medline].

153. Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990 Sep 1. 66(5 Suppl):1039-44. [Medline].

154. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997 Feb. 79(2):235-46. [Medline].

155. Calais da Silva FE, Bono AV, Whelan P, Brausi M, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009 Jun. 55(6):1269-77. [Medline].

156. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4. 368(14):1314-25. [Medline].

157. Fizazi K, Tran N, Fein L, et al; LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017 Jul 27. 377 (4):352-360. [Medline]. [Full Text].

158. James ND, de Bono JS, Spears MR, et al, for the STAMPEDE investigators. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. June 3, 2017. [Full Text].

159. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 Jul 11. 381 (2):121-131. [Medline].

160. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov 10. 37 (32):2974-2986. [Medline].

161. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 5. 42 (9):863-6. [Medline]. [Full Text].

162. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19. 387 (10024):1163-77. [Medline].

163. Shore ND, Saad F, Cookson MS, et al, and the, HERO Study Investigators. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 Jun 4. 382 (23):2187-2196. [Medline].

164. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 7. 379 (9810):39-46. [Medline].

165. Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017 Jun. 20 (2):221-227. [Medline].

166. Qi WX, Shen Z, Yao Y. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. J Cancer Res Clin Oncol. 2011 Dec. 137(12):1785-90. [Medline].

167. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7. 351 (15):1513-20. [Medline].

168. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7. 351(15):1502-12. [Medline].

169. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10. 26(2):242-5. [Medline].

170. Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, et al. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 Jul 11. [Medline].

171. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29. 363 (5):411-22. [Medline]. [Full Text].

172. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26. 364(21):1995-2005. [Medline]. [Full Text].

173. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct. 13(10):983-92. [Medline].

174. US Food and Drug Administration. FDA expands Zytiga’s use for late-stage prostate cancer. December 10, 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm331492.htm. Accessed: December 17, 2012.

175. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27. 367(13):1187-97. [Medline].

176. Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016 Feb. 17 (2):153-63. [Medline].

177. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018 Jun 28. 378 (26):2465-2474. [Medline].

178. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2. 376(9747):1147-54. [Medline].

179. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Feb 8. [Medline]. [Full Text].

180. Fizazi K, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Mar 28. 380 (13):1235-1246. [Medline]. [Full Text].

181. Abida W, Campbell D, Patnaik A, Sautois B, Shapiro J, Vogelzang NJ, et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann Oncol 2019;30 (suppl 5):abst 846PD. [Full Text].

182. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Apr 28. [Medline].

183. Targeted Therapy Slows Progression of Advanced Prostate Cancer [ESMO 2019 Press Release]. European Society for Medical Oncology. Available at https://www.esmo.org/Press-Office/Press-Releases/ESMO-Congress-prostate-cancer-olaparib-Profound-Hussain. September 30, 2019; Accessed: December 19, 2019.

184. Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Sep 20. [Medline].

185. Brooks M. FDA Grants Expanded Indication for Enzalutamide (Xtandi). Medscape Medical News. Available at http://www.medscape.com/viewarticle/831548. Accessed: September 14, 2014.

186. Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 Jun 20. [Medline].

187. Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011 Jul 6. CD003347. [Medline].

188. US Food and Drug Administration. FDA approves new drug for advanced prostate cancer [press release]. May 15, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352363.htm. Accessed: July 1, 2013.

189. Chustecka Z. Xofigo (Radium-223) Approved for Prostate Cancer with Bone Mets. Medscape Medical News. Available at http://www.medscape.com/viewarticle/804184. Accessed: June 11, 2013.

190. Brady D, Parker CC, O'Sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. Cancer J. 2013 Jan. 19(1):71-8. [Medline].

191. Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov. 15 (12):1397-406. [Medline].

192. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012 Sep 10. 30(26):3271-6. [Medline]. [Full Text].

193. FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases. U.S. Food & Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm. October 20, 2010; Accessed: February 16, 2018.

194. Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010 Dec 1. 102(23):1760-70. [Medline]. [Full Text].

195. Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2012 Mar. 187(3):889-93. [Medline].

196. Mulcahy N. New Risk With ADT in Prostate Cancer: Kidney Injury. Medscape Medical News. Available at http://www.medscape.com/viewarticle/807893. Accessed: July 23, 2013.

197. Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013 Jul 17. 310(3):289-96. [Medline].

198. Boonen S, Reginster JY, Kaufman JM, Lippuner K, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012 Nov. 367(18):1714-23. [Medline].

199. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20. 361(8):745-55. [Medline]. [Full Text].

200. Fizazi K, Carducci M, Smith M, Damião R, Brown J, etc. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5. 377(9768):813-22. [Medline]. [Full Text].

201. [Guideline] Laidman J. New ACS Guide for PCPs Managing Prostate Cancer Survivors. Medscape Medical News. Jun 11 2014. [Full Text].

202. [Guideline] Bankhead C. Prostate Ca Guidelines Center on Primary Care. MedPage Today. Jun 11 2014. [Full Text].

203. Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008 Jan 1. 112(1):55-60. [Medline].

204. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B,et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011 Apr. 59(4):477-94. [Medline].

205. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009 Jan 7. 301(1):52-62. [Medline]. [Full Text].

206. Lippman SM, Klein EA, Goodman PJ, Lucia MS, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7. 301(1):39-51. [Medline].

207. Liu Y, Hu F, Li D, Wang F, Zhu L, Chen W, et al. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur Urol. 2011 Nov. 60(5):1029-44. [Medline].

208. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17. 349(3):215-24. [Medline].

209. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1. 362(13):1192-202. [Medline].

210. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17. 349 (3):215-24. [Medline].

211. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008 Aug. 1 (3):174-81. [Medline].

212. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011 Jan. 185 (1):126-31. [Medline].

213. Kramer BS, Hagerty KL, Justman S, Somerfield MR, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009 Mar 20. 27(9):1502-16. [Medline]. [Full Text].

214. FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. U.S. Food & Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm. June 9, 2011; Accessed: February 16, 2018.

215. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24. 379(9821):1103-11. [Medline].

216. [Guideline] Screening for Prostate Cancer: Current Recommendation. US Preventive Services Task Force. May 2012. U.S. Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening?ds=1&s=prostate. May 8, 2018; Accessed: May 22, 2020.

217. [Guideline] Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013 Apr 9. [Medline].

218. Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep. 26 Suppl 5:v69-77. [Medline]. [Full Text].

219. [Guideline] Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. American Urological Association. Available at https://www.auanet.org/guidelines/early-detection-of-prostate-cancer-(2013-reviewed-and-validity-confirmed-2015). 2015; Accessed: February 16, 2018.

220. [Guideline] Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-SIOG GUIDELINES ON PROSTATE CANCER. European Association of Urology. Available at http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2016.pdf. March 2016; Accessed: September 14, 2020.

221. Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010 Dec 1. 304(21):2373-80. [Medline]. [Full Text].

222. [Guideline] Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, et al. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016 Jun 20. 34 (18):2182-90. [Medline]. [Full Text].

223. [Guideline] Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20. 32 (30):3436-48. [Medline].

224. [Guideline] Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 Jan 15. JCO1902757. [Medline].

225. DeCastro GJ, Jayram G, Razmaria A, Shalhav A, Zagaja GP. Functional outcomes in African-Americans after robot-assisted radical prostatectomy. J Endourol. 2012 Aug. 26(8):1013-9. [Medline].

226. Smith MR, Saad F, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 7. 379(9810):39-46. [Medline].

227. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol. 2008 Aug. 54(2):344-52. [Medline].

228. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999 Dec 9. 341(24):1781-8. [Medline].

229. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009 Jun 11. 360(24):2516-27. [Medline].

230. Bria E, Cuppone F, Giannarelli D, Milella M, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer. 2009 Aug 1. 115(15):3446-56. [Medline].

231. Mulcahy N. Radiotherapy Plus ADT Benefit Confirmed in High-risk Prostate Cancer. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/819946. Accessed: February 3, 2014.

232. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012 Jan 12. 366(2):141-9. [Medline].

233. Fowler JE Jr, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. J Urol. 2000 May. 163(5):1467-70. [Medline].

234. Scavonetto F, Yeoh TY, Umbreit EC, et al. Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. Br J Anaesth. 2013 Dec 16. [Medline].

235. Markert EK, Mizuno H, Vazquez A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A. 2011 Dec 27. 108(52):21276-81. [Medline]. [Full Text].

236. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018 Sep 5. 362:k3519. [Medline]. [Full Text].

237. American Urological Association. AUA Disputes Panel’s Recommendations on Prostate Cancer Screening. Available at https://www.prnewswire.com/news-releases/aua-disputes-panels-recommendations-on-prostate-cancer-screening-152349275.html. May 21, 2012; Accessed: August 6, 2019.

238. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26. 360(13):1310-9. [Medline]. [Full Text].

239. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26. 360(13):1320-8. [Medline].

240. Page EC, Bancroft EK, Brook MN, et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 Sep 16. [Medline]. [Full Text].

241. Ahmed HU, Bosaily AE-S, Brown LC, et al; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 19 January 2017. [Full Text].

242. Cornelis F, Rigou G, Le Bras Y, et al. Real-time contrast-enhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings. Radiology. 2013 Oct. 269(1):159-66. [Medline].

243. Stewart GD, Van Neste L, Delvenne P, Delrée P, Delga A, McNeill SA, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013 Mar. 189 (3):1110-6. [Medline].

244. National Cancer Institute. Prostate Cancer Screening (PDQ®). Available at http://www.cancer.gov/cancertopics/pdq/screening/prostate/HealthProfessional/allpages. April 22, 2020; Accessed: May 22, 2020.

245. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012 Jan 9. 344:d7894. [Medline]. [Full Text].

246. Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K, et al. Prospective head-to-head comparison of ¹¹C-choline-PET/MR and ¹¹C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Dec. 44 (13):2179-2188. [Medline].

247. [Guideline] Expert Panel on Urologic Imaging:., Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, et al. ACR Appropriateness Criteria^® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. J Am Coll Radiol. 2017 May. 14 (5S):S245-S257. [Medline].

248. Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen WD, Brelin A, et al. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1. 81(1):29-34. [Medline].

249. Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer. 2002 Sep 1. 95(5):1016-21. [Medline].

250. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer. JAMA Intern Med. 2014 Jul 14. [Medline].

251. Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocerossa F, Ferro M, et al. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer Prostatic Dis. 2019 May. 22 (2):206-220. [Medline].

252. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012 Apr 18. 307(15):1611-20. [Medline].

253. Briganti A, Wiegel T, Joniau S, Cozzarini C, Bianchi M, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012 Sep. 62(3):472-87. [Medline].

254. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011 Apr. 59(4):572-83. [Medline].

255. de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, et al. Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010 Jul. 21(7):795-805. [Medline].

256. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018 Jun. 19 (6):825-833. [Medline].

257. McBean R, O'Kane B, Parsons R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2019 Apr 25. [Medline].

258. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.

259. [Guideline] Cookson MS, Roth BJ, Dahm P, et al. Castration-Resistant Prostate Cancer: AUA Guideline. American Urological Association. Available at https://www.auanet.org/guidelines/castration-resistant-prostate-cancer-(2013-amended-2015). Published 2013; Amended 2018; Accessed: December 29, 2020.

260. Kishan AU, Cook RR, Ciezki JP, ... King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 Mar 6. 319 (9):896-905. [Medline].

Chad R Tracy, MD Assistant Professor, Department of Urology, University of Iowa, Roy J and Lucille A Carver College of Medicine

Chad R Tracy, MD is a member of the following medical societies: American Medical Association, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Nathan A Brooks, MD Resident Physician, Department of Urology, University of Iowa Hospitals and Clinics

Nathan A Brooks, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Mohammed Said, MD Fellow in Minimally Invasive Surgery and Endourology, Department of Urology, University of Iowa, Roy J and Lucille A Carver College of Medicine

Disclosure: Nothing to disclose.

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American Society for Reproductive Medicine, American Urological Association, Sexual Medicine Society of North America, Society for Male Reproduction and Urology, Society for the Study of Male Reproduction, Tennessee Medical Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Endo.

Tracey L Krupski, MD, MPH Assistant Professor, Department of Urology, University of Virginia School of Medicine

Tracey L Krupski, MD, MPH is a member of the following medical societies: American Medical Association, American Urological Association, American Society of Clinical Oncology, Society of Women in Urology

Disclosure: Nothing to disclose.

Bagi RP Jana, MD, MBA, MHA, FACP Professor of Cancer Medicine, MD Anderson Cancer Center; Professor of Medicine, University of Texas Medical Branch at Galveston

Bagi RP Jana, MD, MBA, MHA, FACP is a member of the following medical societies: American Cancer Society, American Medical Association, American Society of Clinical Oncology, SWOG

Disclosure: Nothing to disclose.

Gerald W Chodak, MD &#0134; Editor, www.ProstateVideos.com; Medscape Urology, Experts and Viewpoints--Controversies in Urology; Director of Medical Content, Answers Media, LLC; Author, Winning the Battle Against Prostate Cancer

Gerald W Chodak, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Isamettin Andrew Aral, MD, MSc Attending Physician, Nassau Radiologic Group (Long Island Radiation Therapy); Clinical Assistant Professor of Radiation Oncology, State University of New York Downstate College of Medicine

Isamettin Andrew Aral, MD, MSc, is a member of the following medical societies: American College of Radiology, American Medical Association, and American Society for Therapeutic Radiology and Oncology

Disclosure: Nothing to disclose.

Hassan Aziz, MD Clinical Professor, Department of Radiation Oncology, Downstate Medical Center and Long Island College Hospital, State University of New York at Downstate

Hassan Aziz, MD is a member of the following medical societies: American College of Radiology and American Society for Therapeutic Radiology and Oncology

Disclosure: Nothing to disclose.

Michael Giasullo, MD Clinical Assistant Professor, Department of Urology, State University of New York Downstate Medical Center; Chief, Department of Surgery, Division of Urology, Lutheran Medical Center; Consulting Staff, Bay Ridge Urology Associates; Assistant Attending Physician, Department of Surgery, Urology Section, Methodist Hospital

Michael Giasullo, MD is a member of the following medical societies: American Medical Association and American Urological Association

Disclosure: Nothing to disclose.

Leonard Gabriel Gomella, MD, FACS The Bernard W Godwin Professor of Prostate Cancer Chairman, Department of Urology, Associate Director of Clinical Affairs, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Leonard Gabriel Gomella, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Urological Association, Sigma Xi, Society for Basic Urologic Research, Society of University Urologists, and Society of Urologic Oncology

Disclosure: GSK Consulting fee Consulting; Astra Zeneca Honoraria Speaking and teaching; Watson Pharmaceuticals Consulting fee Consulting

Fazal Hussain, MD, MBBS Director, Clinical Research, King Faisal Cancer Centre

Fazal Hussain, MD, MBBS is a member of the following medical societies: American College of Radiology

Disclosure: Nothing to disclose.

Nicholas Karanikolas, MD Associate Professor, Department of Urology, SUNY Downstate College of Medicine; Director, Urologic Oncology, Staten Island University Hospital; Attending Physician, Department of Urology, Brooklyn Veterans Administration Hospital

Nicholas Karanikolas, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Dan Theodorescu, MD, PhD Paul A Bunn Professor of Cancer Research, Professor of Surgery and Pharmacology, Director, University of Colorado Comprehensive Cancer Center

Dan Theodorescu, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Urological Association, Medical Society of Virginia, Society for Basic Urologic Research, and Society of Urologic Oncology

Disclosure: Key Genomics Ownership interest Co-Founder-50% Stock Ownership; KromaTiD, Inc Stock Options Board membership

• Print this section
• Print the entire contents of
• Print the entire contents of article